People: ACTIVE Biotech AB (ACTI.ST)
49.80SEK
24 May 2013
-1.20kr (-2.35%)
51.00kr
51.50kr
52.00kr
49.00kr
160,395
126,771
69.50kr
37.00kr
Tuvesson, Helen
Brief Biography
Ms. Helen Tuvesson has served as Chief Scientific Officer at Active Biotech AB since April 1, 2011. She was previously Head of Preclinical Development at the Company until April 1, 2011. Ms. Tuvesson has been employed at Active Biotech AB since 1998. She has worked in the pharmaceutical industry for almost 20 years and has held various positions at Pharmacia.
Basic Compensation
| Total Annual Compensation, | Long-Term Incentive Plans, | All Other, | Fiscal Year Total, |
|---|---|---|---|
| -- | -- | -- | -- |
Options Compensation
| Quantity | Market Value | |
|---|---|---|
| Excercisable | -- | -- |
| Unexercisable | -- | -- |
| Excercised | -- | -- |
| Name | Fiscal Year Total |
|---|---|
Mats Arnhog |
250,000 |
Tomas Leanderson |
5,190,000 |
Hans Kolam |
-- |
Helen Tuvesson |
-- |
Goran Forsberg |
-- |
Karin Hallbeck |
-- |
Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.
NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
